Novel anthracycline derivatives have now been produced, which exhibit higher antitumor activities and lower toxicities than those of daunomycin, adriamycin etc. that have been clinically used as anticancer agents. That is, a daunomycinone or adriamycinone derivative represented by the general formula (I):
wherein R is a hydrogen atom or a hydroxyl group, and 7-O-(2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone derivative which is an adriamycinone derivative represented by formula (II):
have now been newly synthesized.
The novel anthracycline derivatives having the general formula (I) and formula (II), respectively, show excellent anticancer or antitumor activities and are of low toxicities. These novel compounds are very useful as anticancer or antitumor agents and are expected to be useful for the therapeutic treatments of a variety of cancers and tumors, similarly to daunomycin or adriamycin.
目前已生产出新型
蒽环类衍
生物,与临床上用作抗癌剂的达霉素、
阿霉素等相比,它们具有更高的抗肿瘤活性和更低的毒性。即由通式(I)代表的达霉素酮或
阿霉素酮衍
生物:
其中 R 是氢原子或羟基,7-O-(2,6-二脱氧-6,6,6-三
氟-α-L-来苏己
吡喃糖基)
阿霉素酮衍
生物是由式(II)表示的
阿霉素酮衍
生物:
的
阿霉素衍
生物。
分别具有通式(I)和式(II)的新型
蒽环类衍
生物显示出卓越的抗癌或抗肿瘤活性,而且毒性低。这些新型化合物作为抗癌剂或抗肿瘤剂非常有用,有望与达霉素或
阿霉素类似,用于各种癌症和肿瘤的治疗。